£0
The seed round was led by Meltwind and Start Codon to accelerate in vivo proof-of-concept studies.
S
Spirea
Spirea develops next-generation antibody-drug conjugate therapeutics for cancer treatment.
Spirea is a University of Cambridge spin-out developing an antibody-drug conjugate platform to improve cancer treatments. The firm aims to deliver higher drug payloads to tumour cells with greater efficacy and tolerability.
Categories
Founders
MO
Myriam Ouberai
CEO
Myriam is the founder and chief scientific officer of Spirea. She previously served as the company's chief executive officer and spent seven years as a senior research associate at the University of Cambridge Nanoscience Centre.
LinkedInInvestors
